Mastering breathlessness in patients with advanced respiratory disease  by Radbruch, Lukas
Comment
944 www.thelancet.com/respiratory   Vol 2   December 2014
 Mastering breathlessness in patients with advanced 
respiratory disease
In The Lancet Respiratory Medicine, Irene Higginson and 
colleagues report the results of a randomised controlled 
trial1 of an early integrated breathlessness support 
service for patients with refractory breathlessness. 
They assessed mastery of breathlessness as the primary 
outcome, a composite score from four questions on 
feeling of control over the disease and its eﬀ ects on 
quality of life and function. Mastery of breathlessness 
was improved in the intervention group at 6 weeks 
compared with the control group. By contrast, the 
authors reported no signiﬁ cant diﬀ erences between 
intervention and control for all secondary outcomes 
including intensity of average breathlessness and 
breathlessness on exertion. The study reported 
improved outcomes for patients with chronic 
obstructive pulmonary disease and interstitial lung 
disease, but not for patients with cancer.
The study shows the beneﬁ ts of early integration of 
palliative care in patients with advanced pulmonary 
diseases. Similar results have been published for 
patients with cancer2–4 and in a smaller trial from 
the same research group for patients with multiple 
sclerosis.5 All these studies have used straightforward 
interventions, with few palliative care consultations. 
Therefore, treatment costs were not increased with 
the palliative-care intervention, because staﬀ  costs for 
the intervention were probably balanced by a reduced 
number of expensive treatments after the palliative-care 
consultation. 
The most astonishing outcome of the study was 
the improved survival in the intervention group. This 
is the ﬁ rst study reporting such a survival advantage 
with palliative care outside of studies of patients with 
cancer. This ﬁ nding is similar to the study of Temel 
and colleagues,2 who noted a survival advantage of 
3 months (11 months in the intervention group vs 
8 months in the control group) with early palliative care 
for patients with lung cancer. However, in both studies 
survival was only a secondary endpoint, and the studies 
had not been designed to test for survival. In Higginson 
and colleagues’ study,1 the Kaplan-Meier estimates show 
an increased advantage in the intervention group even 
after the ﬁ rst 200 days, but at this time the control 
group had also received the breathlessness intervention, 
so the diﬀ erence between groups should diminish 
rather than increase. This ﬁ nding supports the idea that 
palliative care does not shorten life in comparison with 
more aggressive treatment options, and indeed that 
these aggressive treatment options might shorten the 
lifespan of patients with very advanced disease rather 
than extend it.
A second important part of this publication is 
related to the methodology in palliative-care research. 
The selection of breathlessness mastery instead of 
breathlessness intensity as the primary endpoint points 
at the ongoing discussion on outcome assessment 
in palliative-care research. In a systematic review6 
we identiﬁ ed 528 diﬀ erent outcome assessment 
techniques, with most used only in one publication and 
few that were validated.6 Patient-reported outcome 
measurements are usually preferred as endpoints, but 
no consensus has been reached on which measurements 
should be used.7 The authors present good arguments 
why they selected mastery of breathlessness, but 
nevertheless, if the intensity of breathlessness is not 
improved, what does this mastery mean? Is the eﬀ ect 
of the intervention more related to reduction of anxiety 
than to alleviation of breathlessness? Improved mastery 
might not be enough, if it does not lead to reduced 
levels of breathlessness.
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Assessment of single symptoms can be diﬃ  cult 
in patients undergoing palliative care, with pain, 
breathlessness, anxiety, fatigue, and depression 
inﬂ uencing each other. Thus, comprehensive care 
assess ments for research will need to use multi-
dimensional techniques. However, these longer 
assessments can tax the cognitive and physical 
abilities of patients in palliative care. In the advanced 
stage of disease, patients might not be able to rate 
even straightforward assessments such as numerical 
single-item scales, and palliative care trials in these 
settings often have to resort to proxy ratings from 
caregivers or medical staﬀ . Insistence on patient-
reported measure ments would mean that patients with 
reduced cognitive capacities such as patients in the ﬁ nal 
stage of life could not participate in trials, excluding 
this group of patients that need palliative care most 
from research into optimal symptom control. Even in 
Higginson and colleagues’ trial, selection bias cannot 
be excluded. In 2 years, 216 patients were identiﬁ ed 
as eligible according to a broad range of recruitment 
pathways. Many more patients with refractory 
breathlessness were probably treated in that period. Of 
the 216 patients, only 105 patients participated in the 
trial. This discrepancy might mean that the intervention 
is suitable for only a small subgroup of patients. 
Despite these methodological considerations, the 
authors are to be praised for this controlled trial, 
providing evidence of the beneﬁ ts of early integration 
of palliative care for patients with progressive non-
cancerous lung disease. Other clinical trials on the early 
integration of palliative care are urgently needed that 
investigate survival rates as the primary endpoint. 
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Microbial dysbiosis in bronchiectasis 
Not so long ago we believed that the lower airway 
was sterile in health and, in a proportion of patients 
with chronic lung diseases, became colonised with 
potentially pathogenic microorganisms. This belief was 
clearly nonsense—the airways are open from the nose 
and mouth to the alveoli—yet it took the disruptive 
technology of 16S rRNA sequencing to conﬁ rm the 
presence of a healthy human lung microbiome.1 We 
now conceptualise a model in which alterations to 
this healthy microbiome, or microbial dysbiosis, are 
associated with disease, or with exacerbation of stable 
disease, across various respiratory disorders, including 
bronchiectasis.
This is the age of bronchiectasis. Long neglected, 
research is ﬂ ourishing in this challenging and unpleasant 
condition, exempliﬁ ed by the recent publication of 
landmark randomised controlled trials. One of these 
trials, BLESS,2 was one of three2–4 to report the beneﬁ t of 
long-term macrolides in the prevention of exacerbations 
of bronchiectasis. Although the mechanism might well 
not be antibacterial, at least in the traditional sense, 
long-term use of macrolides nevertheless represents a 
selection pressure on the lung microbiome.5 Thus far we 
have not seen substantive data about such eﬀ ects, but 
a subsidiary analysis6 from BLESS reported by Geraint 
Rogers and colleagues in The Lancet Respiratory Medicine 
changes that, and makes for worrying reading.
The language of the microbiologist can be tricky, 
with data typically reported through changes in the 
Bray-Curtis dissimilarity index.7 Developed to assess 
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